Being important activators of the WNT/β-catenin pathway in colon cancer, tankyrase is a hot topic for drug development and promising clinical data have been reported for several tankyrase-targeting reagents as anti-cancer drugs [6,7]. Here, TNKS is linked to malignant colon neoplasm.